RE: Wait25 Jun 2025 18:57
"With the anticipation of further regular positive newsflow as the Company moves through 2025, including additional data from P140 pre-clinical studies; and licence and collaboration deals across the development portfolio, the Directors have an expectation that this new Lanstead agreement will yield a net gain."
Well, let's get some news out Immupharma!